- Report
- February 2021
- 360 Pages
United States
From €2331EUR$2,400USD£2,011GBP
- Report
- June 2019
- 16 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- June 2019
- 21 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- June 2019
- 18 Pages
Global
€9713EUR$10,000USD£8,379GBP
- Report
- June 2019
- 15 Pages
Japan
€9713EUR$10,000USD£8,379GBP
- Report
- June 2019
- 16 Pages
Global
€9713EUR$10,000USD£8,379GBP
Tybost is a drug used to treat HIV and hepatitis C infections. It is a once-daily, single-tablet regimen that combines two antiretroviral drugs, cobicistat and elvitegravir. Tybost is used in combination with other antiretroviral drugs to treat HIV-1 infection in adults and adolescents aged 12 years and older. It is also used in combination with other antiviral drugs to treat chronic hepatitis C virus (HCV) infection in adults.
Tybost is part of a growing market of infectious diseases drugs, which are used to treat a variety of illnesses caused by viruses, bacteria, fungi, and parasites. These drugs are used to treat a range of conditions, from common colds to more serious illnesses such as HIV and hepatitis C.
The market for infectious diseases drugs is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Gilead Sciences, Merck & Co., Johnson & Johnson, Pfizer, and GlaxoSmithKline. Other companies in the market include Bristol-Myers Squibb, AbbVie, and Novartis. Show Less Read more